ClinicalTrials.gg
RecruitingNCT04507412Updated Sep 9, 2026

Intravenous Dexamethasone Administration in Patients Undergoing Total Shoulder Arthroplasty

A Phase 4 interventional study of dexamethasone in Arthroplasty, Replacement, Shoulder, sponsored by Christian Candrian. Recruiting at 1 site in Switzerland. Open to participants aged 58 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Christian Candrian · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
58 Years to 85 Years
Sex
All
01

Study summary

The aim of the study is to evaluate if intravenous steroid supplementation can provide advantages over routine analgesia protocols in terms of post-operative symptoms (pain and nausea), length of hospital stay, shoulder range of motion, function and patient satisfaction

Read the detailed description

The purpose of this study is to detect the efficacy of intravenous perioperative steroid supplementation for total shoulder arthroplasty (TSA) surgeries in terms of short-term and long-term clinical outcomes and to demonstrate its advantages over the routine anaesthesia protocol. The comparison will be evaluated in terms of post- operative pain and function, opioids and analgesic drugs consumption, patient satisfaction, patient reported outcome measures (validated clinical scores), clinician-assessed clinical scores, systemic inflammatory response, length of hospital stay and long-term outcomes. Moreover, to confirm the safety of steroid supplementation all treatment related adverse events- and reactions are going to be recorded and reported, as well as post-operative glycaemia will be monitored.

The primary objective of the study is to show the efficacy on post-operative pain of intravenous perioperative dexamethasone supplementation for TSA.

The secondary objectives of the study are to show superiority by comparison of the intravenous peri- operative dexamethasone supplementation group to the routine analgesia protocol (no steroid supplementation group), in terms of post-operative pain and function, patient satisfaction, shoulder active- and passive range of motion, quantification with validated clinician- and patient reported outcome measures as the Constant, ASES and SSV Scores for function and EQ-5D-3L Score for health-related quality of life, opioids and analgesic drugs consumption, systemic inflammatory response, time until first mobilization and until the patient first slept through at night, the length of hospital stay and presence or absence of a frozen shoulder at the postoperative follow-up, as well as adverse events and reactions, in order to document the advantage over the absence of steroid supplementation in the short-, mid- term- and long-term follow up.

02

Conditions studied

  • Arthroplasty, Replacement, Shoulder

Keywords

  • Total Shoulder Arthroplasty
  • steroid
03

In context

Lead sponsor

Christian Candrian is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
58 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing unilateral primary total anatomical or reverse shoulder arthroplasty (Total Shoulder Arthroplasty)
  • Patients with a >18.5 and \<35
  • Patients able to provide and follow all the study procedures as indicated by the protocol
  • Informed Consent as documented by signature

Exclusion criteria

Exclusion Criteria:

  • to
  • Revision and post-traumatic TSA
  • Active steroid or therapy in the last 30 days before the operation
  • Pregnant or breast-feeding women
  • Presence of other concomitant disease states ()
  • Uncontrolled diabetes mellitus
  • Contraindications to Non-steroidal anti-inflammatory drugs
  • Chronic systemic diseases as immunodeficiency, disease (Systemic Lupus Erythematosus), gout, rheumatic arthritis
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.
  • Participation in another study with drug within the 30 days preceding and during the present study
  • Previous enrolment into the current study
  • Enrolment of the investigator, his/her family members, employees and other dependent persons
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    arm A

    • 9 mg of i.v. dexamethasone

    Drug: dexamethasone

  • No intervention
    arm B

    • no steroid supplementation

Interventions

  • perioperatively 9 mg i.v subministration

    Also known as: Steroids

06

What researchers measure

Primary outcomes

  1. mean post-operative daily pain at rest

    0-10 numeric rating scale (NRS)from 0 to 10, with 10 being most painful

    Time frame: first 3 days after surgery

Secondary outcomes

  1. Post-operative shoulder pain

    0-10 numeric rating scale (NRS)from 0 to 10, with 10 being most painful

    Time frame: first 3 months after surgery

  2. Post-operative shoulder pain

    0-10 numeric rating scale (NRS)from 0 to 10, with 10 being most painful

    Time frame: 2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery

  3. Post-operative global shoulder function score

    0-10 numeric rating scale (NRS)from 0 to 10, with 10 being most functional

    Time frame: daily during the first 3 months

  4. Post-operative global shoulder function score

    0-10 numeric rating scale (NRS)from 0 to 10, with 10 being most functional

    Time frame: 2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery

  5. The clinician assessed Constant score

    The Constant Score questionnaire consists of 8 questions (giving a score of 0 -100, with 100 being the best score) evaluating pain, activity level and range of motion

    Time frame: 2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery

  6. The American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES Score)

    The ASES Score is a patient reported outcome measure (PROM), a validated score evaluating pain and function for daily living and leisure activity. A maximum of 100 points means maximum (normal) functionality and no pain. MCID is 13.6 ± 2.3 points after total shoulder prosthesis

    Time frame: 2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery

  7. The Subjective Shoulder Value (SSV)

    The SSV is a percent of the subjective value of the shoulder given from the patient from 0-100%.

    Time frame: 2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery

  8. European Quality of Life-5 Dimensions-3 Level

    "Health-Related Quality-of-Life Score" and is preferred evaluating cost utility analysis and changes in general health after surgical operations. It contains 5 questions and the maximum (best) score is 1. MCID is 0.07 units

    Time frame: 2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery

  9. PainDETECT

    PainDETECT consists of seven questions that address the quality of pain symptoms; it is completed by the patient and no physical examination is required. A score ≤12 indicates that pain is unlikely to have a neuropathic component (\< 15%), while a score of ≥19 suggests that pain is likely to have a neuropathic component (\> 90%). An intermediate score (≥13, ≤18) indicates a possible neuropathic component.

    Time frame: 2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery

  10. Patient satisfaction

    0-10 numeric rating scale (NRS)

    Time frame: 2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery

  11. Post-operative nausea

    incidence and intensity (on a 0-10 NRS) will be evaluated. The 0-10 NRS is a valid and reliable instrument used for the self- assessment of symptoms: it consists in a single 11-point numeric scale, with 0 indicating no nausea and 10 reflecting the worst possible nausea

    Time frame: first 3 days post-operative days during hospitalisation

  12. Post-operative opioids and analgesic drugs consumption

    Medication Quantification Scale (MQS) score. It is calculated for each medication by taking a consensus-based detriment weight for a given pharmacologic class and multiplying it by a score for dosage. The calculated values for each medication are then summed for a total MQS score. The score can provide a useful point measure of medication usage for any pain medication regime

    Time frame: first 3 days post-operative days during hospitalisation

  13. Postoperative inflammatory response

    This outcome will be evaluated in terms of hematic C-Reactive Protein (CRP) and erythrocyte sedimentation rate (ESR) (the medical chart will be evaluated)

    Time frame: preoperatively and first 3 days post-operative days during hospitalisation

  14. Time from surgery to first mobilization

    Time from surgery to first mobilization

    Time frame: During Hospitalization, approximately 1 days

  15. Rate of frozen shoulders

    This is considered a complication occurring up to 11% and is induced by postoperative inflammatory processes that can lead to adhesive capsulitis

    Time frame: 1 week post-operative during hospitalisation

Other outcomes

  1. Rate of serious adverse events related to steroid supplementation

    Rate of serious adverse events related to steroid supplementation

    Time frame: 2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery

  2. Rate of prosthetic joint infections

    Rate of prosthetic joint infections

    Time frame: 2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery

  3. Rate of wound infections

    Rate of wound infections

    Time frame: 2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery

  4. Rate of wound healing problems

    Rate of wound healing problems

    Time frame: 2 and 6 weeks after surgery and 3, 6, 12, 24, 60 ,120 months after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — not foreseen

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Jul 2032, 142 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2020
First posted
Aug 11, 2020
StartActual
Sep 9, 2020
Primary completionEst.
Jul 31, 2032
CompletionEst.
Aug 31, 2032
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04507412
Lead sponsor
Christian Candrian
Responsible party
Christian Candrian (Principal Investigator, Ente Ospedaliero Cantonale, Bellinzona) — Sponsor-investigator
First posted
Aug 11, 2020
Start date
Sep 9, 2020
Primary completion
Jul 31, 2032 (estimated)
Completion
Aug 31, 2032 (estimated)
Last update
Sep 9, 2026

Study contacts

Christian Candrian, Prof.Dr.med
Contact
christian.candrian@eoc.ch
+41 (0) 91 811 61 23
Gyözö Lehoczky, Dr.med
Contact
Gyoezoe.Lehoczky@eoc.ch
+41918116431
Christian Candrian, Prof.Dr.med
principal investigator · EOC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion